Factor XI1 (Hageman factor) is an important element in several plasma protease cascades such as the blood coagulation system, the kinin system and fibrinolysis (1). Homozygous factor XI1 deficiency with no enzymatic activity is thought to result in a slightly increased risk of venous thromboembolism, but placental thrombosis, myocardial infarction and other thrombotic complications have been reported in some patients (2,3). The factor XI1 protein has the typical features of a member of the serine protease family with the active site residues encoded by the terminal exons 10-14 (4). To date only a few sequence alterations responsible for factor XI1 deficiency were found in these exons (5) (6) (7) (8) . In some patients an additional TaqI site in the second intron of the gene was detected. This TaqI site was not detected in control groups with normal factor XI1 activities (9). We report here a novel mutation termed 11396 (G+A), a G to A transition at nucleotide position 1 1396 of the gene. ~l o o d samples from 12 patients whose low factor XI1 activity was detected by chance during presurgery Table 1 . Genotypes and factor XI1 parameters for factor XI1 deficient patients Patient 11396 (G+A) FX1I:C F XII: Ag PTT (s) *denotes unrelated patients from our group of 12 independent cases; 8 denotes members of the family described in the pedigree (Fig. 2) . Wild type sequence (+), mutant sequence (-), FXI1:C = factor XI1 activity, F X1I:AG = factor XI1 antigen level, PTT = partial thromboplastin time, n.d. = not determined. Table 2 . Primer sequences for analysis of exons 13 and 14 as depicted in Figure 1 screening were collected. Genomic DNA was prepared and analysed by PCR and direct sequencing for mutations .as described (10). RNA preparation and cDNA synthesis with subsequent PCR was performed according to Schloesser et al. (11) . Total RNA from peripheral blood lymphocytes was reverse transcribed by exon 14 specific primer and amplified in two stages with primers located in exons 11, 12 and 14 (Tables 1 and 2 
